Loading…

Impaired fibrinolysis in degenerative mitral and aortic valve stenosis

Valvular heart disease is associated with an increased thromboembolic risk. Impaired fibrinolysis was reported in severe aortic stenosis (AS). Little is known about fibrinolysis in mitral stenosis (MS). We sought to compare fibrinolysis impairment in AS and MS. We studied 121 individuals scheduled f...

Full description

Saved in:
Bibliographic Details
Published in:Journal of thrombosis and thrombolysis 2018-08, Vol.46 (2), p.193-202
Main Authors: Mazur, Piotr, Myć, Jacek, Natorska, Joanna, Plens, Krzysztof, Plicner, Dariusz, Grudzień, Grzegorz, Kapelak, Bogusław, Undas, Anetta
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Valvular heart disease is associated with an increased thromboembolic risk. Impaired fibrinolysis was reported in severe aortic stenosis (AS). Little is known about fibrinolysis in mitral stenosis (MS). We sought to compare fibrinolysis impairment in AS and MS. We studied 121 individuals scheduled for elective aortic valve (AV) or mitral valve (MV) surgery for AS (n = 76) or MS (n = 45), in order to compare fibrinolysis impairment. Fibrinolytic capacity was assessed by determination of clot lysis time (t 50% ) and fibrinolysis inhibitors, including plasma plasminogen activator inhibitor-1 (PAI-1) antigen (PAI-1:Ag) and activity, thrombin-activatable fibrinolysis inhibitor (TAFI) antigen and activity. Prolonged t 50% (+ 29%), elevated TAFI activity (+ 12%), TAFI:Ag (+ 21%), and PAI-1:Ag (+ 84%) were observed in patients with MS, compared with those with AS. t 50% Correlated with mean and maximal MV gradients (r = 0.43, p 
ISSN:0929-5305
1573-742X
DOI:10.1007/s11239-018-1687-1